The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi
Open accessAbstract
The in vitro antifungal activity and spectrum of FK463 were compared with those of amphotericin B, fluconazole, and itraconazole by using a broth microdilution method specified by National Committee for Clinical Laboratory Standards document M27-A (National Committee for Clinical Laboratory Standards, Wayne, Pa., 1997). FK463 exhibited broad-spectrum activity against clinically important pathogens including Candida species (MIC range, ≦0.0039 to 2 μg/ml) and Aspergillus species (MIC range, ≦0.0039 to 0.0313 μg/ml), and its MICs for such fungi were lower than those of the other antifungal agents tested. FK463 was also potently active against azole-resistant Candida albicans as well as azole-susceptible strains, and there was no cross-resistance with azoles. FK463 showed fungicidal activity against C. albicans , i.e., a 99% reduction in viability after a 24-h exposure at concentrations above 0.0156 μg/ml. The minimum fungicidal concentration (MFC) assays indicated that FK463 was fungicidal against most isolates of Candida species. In contrast, the MFCs of FK463 for A. fumigatus isolates were much higher than the MICs, indicating that its action is fungistatic against this species. FK463 had no activity against Cryptococcus neoformans , Trichosporon species, or Fusarium solani . Neither the test medium (kind and pH) nor the inoculum size greatly affected the MICs of FK463, while the addition of 4% human serum albumin increased the MICs for Candida species and A. fumigatus more than 32 times. Results from preclinical in vitro evaluations performed thus far indicate that FK463 should be a potent parenteral antifungal agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
ANTIBIOTICS THAT INHIBIT FUNGAL CELL WALL DEVELOPMENT
Debono, M., & Gordee, R. S. (1994) · Annual Review of Microbiology · doi:10.1146/annurev.mi.48.100194.002351 · Cited by 372
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Fluconazole resistance in Candida glabrata
Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., & Warnock, D. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1962 · Cited by 244
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A. F., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241
Del Poeta, M., Schell, W. A., & Perfect, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1835 · Cited by 164
Petraitis, V., Petraitienė, R., Groll, A. H., Bell, A., Callender, D. P., Sein, T., Schaufele, R. L., McMillian, C. L., Bacher, J. D., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2898 · Cited by 115
Krishnarao, T. V., & Galgiani, J. N. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1957 · Cited by 108
Verweij, P. E., Oakley, K. L., Morrissey, J., Morrissey, G., & Denning, D. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.873 · Cited by 103
Cited by
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“Although the susceptibility of Candida to the currently available antifungal agents can be predicted if the species of the infecting isolate is known (table 3) [1, 4, 6, 11–17, 20– 24], individual isolates do not necessarily follow the general pattern.”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 601
Girmenia, C., Pagano, L., Martino, B., D'Antonio, D., Fanci, R., Specchia, G., Melillo, L., Buelli, M., Pizzarelli, G., Venditti, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1818-1828.2005 · Cited by 397
Dignani, M. C., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00845.x · Cited by 352
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 305
Micafungin: A New Echinocandin
Chandrasekar, P. H., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/501020 · Cited by 256
(2003) · PubMed · Cited by 240
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134
Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3310-3321.2001 · Cited by 117
Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
Cantón, E., Pemán, J., Sastre, M., Romero, M., & Espinel-Ingroff, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00524-06 · Cited by 37
Ueno, K., Namiki, Y., Mitani, H., Yamaguchi, M., & Chibana, H. (2011) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2011.00728.x · Cited by 17
Metadata
- Authors
- Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., & Kuwahara, S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-01
- Volume
- 44
- Issue
- 1
- Pages
- 57-62
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2171516933
- Cited by
- 311
- References
- 18
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.